CordycepsvsPolygala Tenuifolia

Cordycepin (3'-deoxyadenosine), the primary bioactive compound, increases ATP production by enhancing mitochondrial electron transport chain efficiency — it may act as an alternative substrate or modulator of Complex I and Complex III. Cordycepin activates AMPK (AMP-activated protein kinase) via increased AMP/ATP ratio or direct activation of the alpha subunit, promoting glucose uptake through GLUT4 translocation and fatty acid oxidation via CPT-1 and ACC inhibition. Cordyceps increases erythropoietin (EPO) production, likely through HIF-1alpha stabilization in hypoxic-sensitive tissues, improving oxygen-carrying capacity. Cordycepin has adenosine-like activity, modulating purinergic P1 (A1, A2A, A2B, A3) and P2 receptors. Anti-inflammatory effects occur through inhibition of NF-kB (reducing IKK degradation of IkB and nuclear translocation) and reduction of pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha). Adenosine deaminase-resistant cordycepin may also affect RNA polyadenylation.

The saponins (tenuigenin, polygalasaponins, onjisaponins) and oligosaccharide esters (3,6'-disinapoyl sucrose, tenuifolisides) have multiple neurological actions. They inhibit acetylcholinesterase (AChE) at the catalytic site, increasing synaptic acetylcholine and enhancing muscarinic M1/M4 and nicotinic receptor signaling. They promote BDNF and NGF expression via CREB and ERK/MAPK pathways, supporting neuroplasticity and neurogenesis in the hippocampus and subventricular zone. They modulate NMDA receptor function (possibly as positive allosteric modulators at the glycine site) and enhance long-term potentiation (LTP) via CaMKII and PKC. The anti-depressant effects involve monoaminergic modulation — increasing dopamine and norepinephrine via MAO inhibition or reuptake modulation — and HPA axis regulation (reducing CRH and cortisol). Tenuigenin may also activate TrkB receptors directly.